Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,809 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes Clear all
Completed Phase 1 Interventional Results available

Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

NCT05158244
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-07081532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 21, 2026, 11:15 PM EDT
Recruiting Phase 2 Interventional

Islet Transplantation in Type 1 Diabetic Kidney Allograft

NCT01241864
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
Biological · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 68 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Family Routines Enhancing Adolescent Diabetes by Optimizing Management

NCT02974309
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sleep Extension, Routine
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
10 Years to 17 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes

NCT02081014
View directory record Official record
Conditions
Hypoglycemia
Interventions
G-Pen Mini™ (glucagon injection)
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

Context Aware Data Gathering Study

NCT04154904
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Exercise
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 21, 2026, 11:15 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect Pulsatile IV Insulin Therapy on the Quality of Life in Patients With Types 1 and 2 Diabetes

NCT00228878
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Effects of Pulsatile IV insulin on Diabetic Quality of Life
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
21 Years to 85 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes

NCT04113694
View directory record Official record
Conditions
Diabetes
Interventions
Extended Infusion Set
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Escondido, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

NCT01835431
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec/insulin aspart, insulin aspart, insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 17 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 1 Interventional Results available

Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

NCT00836407
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Ipilimumab, Pancreatic Cancer Vaccine
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

NCT02171130
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
Interventions
Nasal Glucagon
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Waltham, Massachusetts • Minneapolis, Minnesota • Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

Development of Algorithms for a Hypoglycemic Prevention Alarm: Closed Loop Study

NCT00884611
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Predictive Low Glucose Suspend Algorithm ON, Predictive Low Glucose Suspend Algorithm OFF
Device
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 46 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 21, 2026, 11:15 PM EDT
Recruiting Not applicable Interventional

Type 1 Diabetes REst for Metabolic Health

NCT06627504
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Sleep Health
Interventions
Sleep Health and Circadian Timing Intervention
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
14 Years to 19 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 2 Interventional

Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

NCT05018416
View directory record Official record
Conditions
Chronic Kidney Diseases, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Denver, Colorado • Newark, Delaware • Nampa, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

New Onset Type 1 Diabetes: Role of Exenatide

NCT01269034
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Exenatide, Rapid and long acting insulin, long acting insulin + rapid acting + 1.25 mcg Exenatide
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 1 Interventional

Rilonacept in Diabetes Mellitus Type 1: Safety Study

NCT00962026
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rilonacept
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
16 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Oct 21, 2026, 11:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Intestinal Inflammation in the Pathogenesis of Type 1 Diabetes

NCT01940835
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Upper endoscopy with small bowel biopsies and brushings., Blood draw, Stool sample
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 21, 2026, 11:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Type 1 Diabetes and Neurocognitive Complications Cohort Study

NCT04135365
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
neurocognitive assessment, neuroimaging assessment
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Years to 11 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 1 Interventional

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

NCT03436498
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin aspart SAR341402, Insulin aspart
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Little Rock, Arkansas • Denver, Colorado • West Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 21, 2026, 11:15 PM EDT
Completed No phase listed Observational

Impact of Hybrid Closed-Loop Systems on Sleep and Psychosocial Outcomes in Youth With T1D and Their Parents

NCT04431947
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 17 Years
Enrollment
46 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 21, 2026, 11:15 PM EDT
Active, not recruiting Not applicable Interventional

The T1D Parent Check-In: A Preventative Intervention

NCT06160934
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes in Children
Interventions
T1D Parent Check-in
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Active, not recruiting No phase listed Observational

Prospective Decision Impact Clinical Utility Trial of KidneyIntelX

NCT05198284
View directory record Official record
Conditions
Diabetic Kidney Disease, Chronic Kidney Diseases, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3
Interventions
KidneyIntelX
Diagnostic Test
Lead sponsor
Renalytix AI, Inc.
Industry
Eligibility
23 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532

NCT01369277
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
PF-04991532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Oct 21, 2026, 11:15 PM EDT
Recruiting Not applicable Interventional

Family Intervention for Black Teens With Type 1 Diabetes

NCT06275412
View directory record Official record
Conditions
Type 1 Diabetes, Family Relations
Interventions
The 3Ms 2.0 Intervention, Educational Attention Control (EAC)
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
10 Years to 14 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Detroit, Michigan • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Withdrawn Not applicable Interventional

Technology Knowledge Optimization in Type 1 Diabetes (TeKnO T1D): Parents

NCT05300022
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
TeKnO T1D: Parents
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 21, 2026, 11:15 PM EDT